Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4
Table 1
Baseline clinical, virological, and histological features of sixty-two HCV patients and comparison of these features between responder and nonresponder patients to treatment.
Characteristics
HCV patients
Responders
Nonresponders
P value
(66.1%)
(33.9%)
Male/female
51/11
34/7
17/4
1.000
Age (mean ± S.E)
40.53 ± 1.17
39.44 ± 1.5
42.67 ± 1.67
0.160
Liver function
ALT (IU/L)
(mean ± S.E)
73.9 ± 4.5
67.93 ± 5
85.62 ± 8
0.041
#
AST (IU/L)
(mean ± S.E)
61.6 ± 4.9
61.44 ± 7.13
61.9 ± 4.5
0.956
AFP (U/L)
(mean ± S.E)
7.1 ± 1.5
6.7 ± 2.1
7.78 ± 1.6
0.692
HCV-RNA level
Low
20 (32.3%)
12 (29.3%)
8 (38.1%)
0.035
#
Moderate
27 (43.5%)
21 (51.2%)
6 (28.6%)
High
5 (8.1%)
2 (4.9%)
3 (14.3%)
Unknown
10 (16.1%)
6 (14.6%)
6 (28.6%)
Activity score
A1
49 (79%)
35 (85.4%)
14 (66.7%)
0.044
#
A2
13 (21%)
6 (14.6%)
7 (33.3%)
Fibrosis score
F1
28 (45.2%)
21 (51.2%)
7 (33.3%)
0.05
#
F2
20 (32.3%)
14 (34.1%)
6 (28.6%)
F3
14 (22.6%)
6 (14.6%)
8 (38.1%)
Significant difference at P ≤ 0.05; between responder and nonresponder patients to treatment. No patients had A0 or A3 activity and F0 or F4 fibrosis.
